FOURTH CONFERENCE ON DNA TOPOISOMERASES IN THERAPY

我们建议在中国举办“第四届DNA拓扑异构酶大会” 治疗“将于1992年10月17日至19日在纽约大学医学中心举行。 不仅讨论抗癌药物及其靶向DNA拓扑异构酶I 或II，但也是一种密切相关的酶DNA旋转酶 喹诺酮类药物及相关药物。有一大堆问题，比如酶 遗传学、生物化学、作用机制和抗性，它们是 这两个领域的共同研究要么是开发抗癌药物 有效预防感染的治疗或药剂。准备工作和 会议的组织工作将包括： 1)传播有关会议的信息，邮寄和 科学期刊上的广告或公告。 2)会议的组织工作，将以三年半的形式举行 日会议，有九次全体会议的幻灯片演示，并与 两到三次海报会议。每个幻灯片会议将包括邀请 演讲者，其中大多数是该领域的领先专家，以及 精选提供的论文有三个主要主题 全体会议： (I)原核和真核拓扑异构酶的基础研究，概述 以及新的进展。 (2)喹诺酮类及相关化合物，DNA旋转酶抑制剂， 感染的治疗。 (3)新的抗癌药物，DNA拓扑异构酶I和II的抑制剂， 实验室、先进的临床前和临床研究。 3)以全文形式出版会议讲稿。一次尝试 将以卷的形式出版选定的主题 喜树碱，一类新型抗癌药物。

We propose to organize the "Fourth Conference on DNA Topoisomerases in Therapy" at the NYUMC, in October 17-19, 1992. The conference will discuss not only anticancer agents and their target DNA topoisomerase I or II, but also a closely related enzyme DNA gyrase targeted by quinolones and related drugs. There is a host of problems such as enzyme genetics, biochemistry, mechanism of action and resistance, which are common to these two fields of research either developing anticancer treatment or agents effective against infection. The preparation and organization of the conference will include: 1} Dissemination of information, regarding the conference, by mail and by advertisement or announcements in scientific journals. 2} Organization of the conference which will be held as a three-and-half day meeting, with nine plenary sessions of slide presentations, and with two to three poster sessions. Each slide session will include invited speakers, most of them leading experts in the field, and presenters of selected proffered papers There are three major topics to be covered in plenary sessions: (i) Basic research of prokaryotic and eukaryotic topoisomerases, overview and new advances. (ii) Quinolones and related compounds, inhibitors of DNA gyrase, in therapy of infection. (iii) New anticancer agents, inhibitors of DNA topoisomerase I and II, in laboratory, advanced pre-clinical and clinical research. 3} Publication of conference lectures as full-size articles. An attempt will be made to publish selected topics as a volume focussed on camptothecins, a novel class of anticancer drugs.